These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 31184028)

  • 1. [A role of fructose in urinary stone formation].
    Pavlova ZS; Golodnikov II; Kamalov AA; Nizov AN
    Urologiia; 2019 Apr; (1):114-118. PubMed ID: 31184028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kidney stones diseases and glycaemic statuses: focus on the latest clinical evidences.
    Spatola L; Angelini C; Badalamenti S; Maringhini S; Gambaro G
    Urolithiasis; 2017 Oct; 45(5):457-460. PubMed ID: 27921141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of renal uric acid stones in the adult.
    Trinchieri A; Montanari E
    Urolithiasis; 2017 Dec; 45(6):553-562. PubMed ID: 28258472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uric acid nephrolithiasis: An update.
    Cicerello E
    Urologia; 2018 Aug; 85(3):93-98. PubMed ID: 29687761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic syndrome and urinary stone composition: what factors matter most?
    Kadlec AO; Greco K; Fridirici ZC; Hart ST; Vellos T; Turk TM
    Urology; 2012 Oct; 80(4):805-10. PubMed ID: 22795374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of being overweight on urinary metabolic risk factors for kidney stone formation.
    Shavit L; Ferraro PM; Johri N; Robertson W; Walsh SB; Moochhala S; Unwin R
    Nephrol Dial Transplant; 2015 Apr; 30(4):607-13. PubMed ID: 25362001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Obesity and kidney stone disease: a systematic review.
    Carbone A; Al Salhi Y; Tasca A; Palleschi G; Fuschi A; De Nunzio C; Bozzini G; Mazzaferro S; Pastore AL
    Minerva Urol Nefrol; 2018 Aug; 70(4):393-400. PubMed ID: 29856171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Essential arterial hypertension and stone disease.
    Borghi L; Meschi T; Guerra A; Briganti A; Schianchi T; Allegri F; Novarini A
    Kidney Int; 1999 Jun; 55(6):2397-406. PubMed ID: 10354288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fructose consumption and the risk of kidney stones.
    Taylor EN; Curhan GC
    Kidney Int; 2008 Jan; 73(2):207-12. PubMed ID: 17928824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Obesity and urolithiasis: evidence of regional influences.
    Trinchieri A; Croppi E; Montanari E
    Urolithiasis; 2017 Jun; 45(3):271-278. PubMed ID: 27488444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pathophysiology, diagnosis and conservative therapy in calcium kidney calculi].
    Hess B
    Ther Umsch; 2003 Feb; 60(2):79-87. PubMed ID: 12649986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pathophysiology, diagnosis and conservative therapy of non-calcium kidney calculi].
    Hochreiter W; Knoll T; Hess B
    Ther Umsch; 2003 Feb; 60(2):89-97. PubMed ID: 12649987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Uric acid and fructose: potential biological mechanisms.
    Lanaspa MA; Tapia E; Soto V; Sautin Y; Sánchez-Lozada LG
    Semin Nephrol; 2011 Sep; 31(5):426-32. PubMed ID: 22000649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fructose intake as a risk factor for kidney stone disease.
    Asselman M; Verkoelen CF
    Kidney Int; 2008 Jan; 73(2):139-40. PubMed ID: 18165809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fructose and Uric Acid: Major Mediators of Cardiovascular Disease Risk Starting at Pediatric Age.
    Russo E; Leoncini G; Esposito P; Garibotto G; Pontremoli R; Viazzi F
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32599713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal stone disease and obesity: what is important for urologists and nephrologists?
    Ahmed MH; Ahmed HT; Khalil AA
    Ren Fail; 2012; 34(10):1348-54. PubMed ID: 23013150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The fructose tolerance test in patients with chronic kidney disease and metabolic syndrome in comparison to healthy controls.
    Donderski R; Miśkowiec-Wiśniewska I; Kretowicz M; Grajewska M; Manitius J; Kamińska A; Junik R; Siódmiak J; Stefańska A; Odrowąż-Sypniewska G; Pluta A; Lanaspa M; Johnson RJ
    BMC Nephrol; 2015 May; 16():68. PubMed ID: 25935771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimum nutrition for kidney stone disease.
    Heilberg IP; Goldfarb DS
    Adv Chronic Kidney Dis; 2013 Mar; 20(2):165-74. PubMed ID: 23439376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of visceral fat area and other metabolic parameters on stone composition in patients undergoing percutaneous nephrolithotomy.
    Zhou T; Watts K; Agalliu I; DiVito J; Hoenig DM
    J Urol; 2013 Oct; 190(4):1416-20. PubMed ID: 23685097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sugary drinks in the pathogenesis of obesity and cardiovascular diseases.
    Brown CM; Dulloo AG; Montani JP
    Int J Obes (Lond); 2008 Dec; 32 Suppl 6():S28-34. PubMed ID: 19079277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.